MetLife Investment Advisors LLC Reduces Position in Intellia Therapeutics Inc (NTLA)

MetLife Investment Advisors LLC reduced its position in shares of Intellia Therapeutics Inc (NASDAQ:NTLA) by 35.5% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 15,741 shares of the company’s stock after selling 8,682 shares during the quarter. MetLife Investment Advisors LLC’s holdings in Intellia Therapeutics were worth $215,000 at the end of the most recent quarter.

A number of other hedge funds have also recently bought and sold shares of the stock. BlackRock Inc. raised its stake in shares of Intellia Therapeutics by 4.5% in the fourth quarter. BlackRock Inc. now owns 2,868,738 shares of the company’s stock worth $39,158,000 after purchasing an additional 124,341 shares during the last quarter. Vanguard Group Inc. raised its stake in shares of Intellia Therapeutics by 12.2% in the third quarter. Vanguard Group Inc. now owns 2,653,165 shares of the company’s stock worth $75,934,000 after purchasing an additional 287,682 shares during the last quarter. Vanguard Group Inc raised its stake in shares of Intellia Therapeutics by 12.2% in the third quarter. Vanguard Group Inc now owns 2,653,165 shares of the company’s stock worth $75,934,000 after purchasing an additional 287,682 shares during the last quarter. Ontario Teachers Pension Plan Board purchased a new stake in shares of Intellia Therapeutics in the fourth quarter worth approximately $22,659,000. Finally, Federated Investors Inc. PA raised its stake in shares of Intellia Therapeutics by 6.8% in the third quarter. Federated Investors Inc. PA now owns 667,525 shares of the company’s stock worth $19,105,000 after purchasing an additional 42,225 shares during the last quarter. 69.64% of the stock is currently owned by institutional investors and hedge funds.

Shares of NTLA opened at $16.15 on Friday. The company has a market cap of $730.38 million, a P/E ratio of -8.16 and a beta of 2.95. Intellia Therapeutics Inc has a 12 month low of $11.03 and a 12 month high of $32.95.

Intellia Therapeutics (NASDAQ:NTLA) last issued its quarterly earnings results on Wednesday, February 27th. The company reported ($0.43) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.55) by $0.12. The company had revenue of $7.90 million during the quarter, compared to the consensus estimate of $9.92 million. Intellia Therapeutics had a negative return on equity of 30.59% and a negative net margin of 280.42%. Intellia Therapeutics’s revenue was up 17.9% on a year-over-year basis. During the same period last year, the business posted ($0.61) earnings per share. As a group, research analysts anticipate that Intellia Therapeutics Inc will post -2.47 EPS for the current fiscal year.

Several brokerages have recently commented on NTLA. BidaskClub downgraded Intellia Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, April 16th. Evercore ISI began coverage on Intellia Therapeutics in a research note on Thursday, April 11th. They issued an “outperform” rating for the company. Chardan Capital reissued a “buy” rating and issued a $57.50 price objective on shares of Intellia Therapeutics in a research note on Wednesday, February 27th. BTIG Research began coverage on Intellia Therapeutics in a research note on Thursday, February 7th. They issued a “buy” rating and a $20.00 price objective for the company. Finally, Zacks Investment Research downgraded Intellia Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, January 29th. Eight equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. Intellia Therapeutics presently has a consensus rating of “Hold” and an average target price of $29.08.

In other Intellia Therapeutics news, EVP Andrew Schiermeier purchased 7,500 shares of the firm’s stock in a transaction that occurred on Wednesday, March 6th. The stock was bought at an average cost of $15.72 per share, with a total value of $117,900.00. Following the completion of the transaction, the executive vice president now owns 3,250 shares of the company’s stock, valued at approximately $51,090. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 3.20% of the company’s stock.

WARNING: This piece of content was first reported by Baseball Daily News and is the sole property of of Baseball Daily News. If you are viewing this piece of content on another site, it was illegally stolen and reposted in violation of international trademark and copyright laws. The legal version of this piece of content can be accessed at https://www.baseballdailydigest.com/news/2019/04/21/metlife-investment-advisors-llc-reduces-position-in-intellia-therapeutics-inc-ntla.html.

Intellia Therapeutics Profile

Intellia Therapeutics, Inc, a gene editing company, focuses on the development of therapeutics utilizing a biological tool known as the CRISPR/Cas9 system. The company develops in vivo programs focused on liver diseases, including transthyretin amyloidosis, alpha-1 antitrypsin deficiency, hepatitis B virus, and inborn errors of metabolism programs.

Featured Article: What is the balance sheet?

Want to see what other hedge funds are holding NTLA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Intellia Therapeutics Inc (NASDAQ:NTLA).

Institutional Ownership by Quarter for Intellia Therapeutics (NASDAQ:NTLA)

Receive News & Ratings for Intellia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.